secwatch.observer — SEC 8-K summary
======================================

Issuer:     TELA Bio, Inc. (TELA)
CIK:        0001561921
Form:       8-K
Filed at:   2026-08-10T20:12:20+00:00
Accession:  0001104659-26-093371
Event type: earnings
Sentiment:  negative
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

TELA Bio Q2 revenue down 4% to $19.3M, withdraws FY2026 guidance
----------------------------------------------------------------

- Q2 2026 revenue $19.3M, down 4% from $20.2M; gross margin 72% vs 70%.
- Net loss widened to $11.3M from $9.9M; operating loss $9.3M; cash $30.4M.
- Heather Getz appointed CEO and Director effective August 4, 2026.
- International revenue up 26%, OviTex units up 12%, LiquiFix revenue up 39% YoY.
- Full-year 2026 revenue guidance withdrawn; company cites PRS volume decline.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1561921/000110465926093371/0001104659-26-093371-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1561921/000110465926093371/tm2622768d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-093371

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer